These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 30626715)

  • 1. Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.
    Lucey BP; McCullough A; Landsness EC; Toedebusch CD; McLeland JS; Zaza AM; Fagan AM; McCue L; Xiong C; Morris JC; Benzinger TLS; Holtzman DM
    Sci Transl Med; 2019 Jan; 11(474):. PubMed ID: 30626715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NREM sleep as a novel protective cognitive reserve factor in the face of Alzheimer's disease pathology.
    Zavecz Z; Shah VD; Murillo OG; Vallat R; Mander BA; Winer JR; Jagust WJ; Walker MP
    BMC Med; 2023 May; 21(1):156. PubMed ID: 37138290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subthreshold Amyloid Predicts Tau Deposition in Aging.
    Leal SL; Lockhart SN; Maass A; Bell RK; Jagust WJ
    J Neurosci; 2018 May; 38(19):4482-4489. PubMed ID: 29686045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bidirectional relationship between sleep and Alzheimer's disease: role of amyloid, tau, and other factors.
    Wang C; Holtzman DM
    Neuropsychopharmacology; 2020 Jan; 45(1):104-120. PubMed ID: 31408876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau and Aβ imaging, CSF measures, and cognition in Alzheimer's disease.
    Brier MR; Gordon B; Friedrichsen K; McCarthy J; Stern A; Christensen J; Owen C; Aldea P; Su Y; Hassenstab J; Cairns NJ; Holtzman DM; Fagan AM; Morris JC; Benzinger TL; Ances BM
    Sci Transl Med; 2016 May; 8(338):338ra66. PubMed ID: 27169802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sleep as a Potential Biomarker of Tau and β-Amyloid Burden in the Human Brain.
    Winer JR; Mander BA; Helfrich RF; Maass A; Harrison TM; Baker SL; Knight RT; Jagust WJ; Walker MP
    J Neurosci; 2019 Aug; 39(32):6315-6324. PubMed ID: 31209175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective disruption of the cerebral neocortex in Alzheimer's disease.
    Desikan RS; Sabuncu MR; Schmansky NJ; Reuter M; Cabral HJ; Hess CP; Weiner MW; Biffi A; Anderson CD; Rosand J; Salat DH; Kemper TL; Dale AM; Sperling RA; Fischl B;
    PLoS One; 2010 Sep; 5(9):e12853. PubMed ID: 20886094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
    Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
    J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sleep Disturbance Forecasts β-Amyloid Accumulation across Subsequent Years.
    Winer JR; Mander BA; Kumar S; Reed M; Baker SL; Jagust WJ; Walker MP
    Curr Biol; 2020 Nov; 30(21):4291-4298.e3. PubMed ID: 32888482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased Medial Temporal Tau Positron Emission Tomography Uptake in the Absence of Amyloid-β Positivity.
    Costoya-Sánchez A; Moscoso A; Silva-Rodríguez J; Pontecorvo MJ; Devous MD; Aguiar P; Schöll M; Grothe MJ;
    JAMA Neurol; 2023 Oct; 80(10):1051-1061. PubMed ID: 37578787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF tau368/total-tau ratio reflects cognitive performance and neocortical tau better compared to p-tau181 and p-tau217 in cognitively impaired individuals.
    Simrén J; Brum WS; Ashton NJ; Benedet AL; Karikari TK; Kvartsberg H; Sjons E; Lussier FZ; Chamoun M; Stevenson J; Hopewell R; Pallen V; Ye K; Pascoal TA; Zetterberg H; Rosa-Neto P; Blennow K
    Alzheimers Res Ther; 2022 Dec; 14(1):192. PubMed ID: 36544221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
    Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
    Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tau Accumulation in Clinically Normal Older Adults Is Associated with Hippocampal Hyperactivity.
    Huijbers W; Schultz AP; Papp KV; LaPoint MR; Hanseeuw B; Chhatwal JP; Hedden T; Johnson KA; Sperling RA
    J Neurosci; 2019 Jan; 39(3):548-556. PubMed ID: 30482786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease.
    Pereira JB; Janelidze S; Smith R; Mattsson-Carlgren N; Palmqvist S; Teunissen CE; Zetterberg H; Stomrud E; Ashton NJ; Blennow K; Hansson O
    Brain; 2021 Dec; 144(11):3505-3516. PubMed ID: 34259835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Trajectory of Cerebrospinal Fluid Growth-Associated Protein 43 in the Alzheimer's Disease Continuum: A Longitudinal Study.
    Zhang H; Lyu D; Jia J;
    J Alzheimers Dis; 2022; 85(4):1441-1452. PubMed ID: 34958042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metabolic correlates of CSF Tau protein in a large cohort of Alzheimer's disease patients: A CSF and FDG PET study.
    Chiaravalloti A; Barbagallo G; Ricci M; Martorana A; Ursini F; Sannino P; Karalis G; Schillaci O
    Brain Res; 2018 Jan; 1678():116-122. PubMed ID: 29066367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition.
    Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N
    Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.